Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy
In brief
The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of a single, daily, oral dose of ST-246 (either 250, 400 or 800mg) administered for 21 days to 30 healthy, fed volunteers.
Key facts
- Study ID
- NCT00431951
- Run by
- SIGA Technologies
- People needed
- 30
- Starts
- 2007-02-01
- Expected to finish
- 2008-02-01
- Last updated by the study team
- 2017-07-27
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.
Where it is running
- Orlando Clinical Research — Orlando, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.